Fatma Hümeyra YERLİKAYA, Makbule Tuğba TUNÇDEMİR

Amalgam Dolgulu Hastalarda ve Diş Hekimlerinde PlazmaMikroRNA'lar ile Serum Civa Düzeyleri Arasındaki İlişki

Amaç: Bu çalışmanın amacı, amalgam dolgusu olanhastalarda ve diş hekimlerinde serum civa ve nörolojikhastalıklarla ilişkili bazı plazma mikroRNA (miRNA) seviyeleriarasındaki ilişkiyi araştırmaktır. Gereç ve Yöntemler: Bu çalışmaya 30 amalgam dolguluhasta, 30 amalgam dolgusu olmayan diş hekimi ve 30 sağlıklıkontrol grubu dahil edildi. Dolaşımdaki plazma miRNA'lar (124- 3p, 125-5p ve 127-3p), gerçek zamanlı kantitatif polimerazzincir reaksiyonu analizi kullanılarak değerlendirildi. Serum civaseviyeleri, endüktif olarak eşleşmiş plazma-kütlespektrometresi kullanılarak ölçüldü. İstatistiksel analizler içinANOVA ve Tukey’in çoklu karşılaştırma testleri kullanıldı (α =.05). Bulgular: Gruplar arasında serum civa ve plazma miRNAseviyelerinde anlamlı bir fark bulundu. Hasta grubunda serumciva ile plazma miRNA 125-5p ve 127-3p seviyeleri arasındaanlamlı pozitif korelasyonlar tespit edildi (sırasıyla r: 0.56 ve r:0.39). Serum civa ve plazma miRNA-125-5p seviyeleri, dişhekimi grubunda pozitif bir korelasyon gösterdi (r: 0.37). Sonuç: Amalgam dolguya sahip olmak serum civa ve bazıplazma miRNA düzeylerinde önemli bir artışa neden olmuştur.Pozitif bir korelasyonun varlığı, civa maruziyeti nedeniylenörolojik hastalıklara duyarlılığın artabileceğini göstermektedir.Amalgam dolgu için alternatif restoratif materyaller tercihedilmeli ve amalgam dolgular, gerekli önlemler alınarak diğerrestoratif materyaller ile değiştirilmelidir.

The Relationship Between Plasma MicroRNAs and SerumMercury Levels in Patients with Amalgam Filling and Dentists

Background: The aim of this study was to investigate therelationship between serum mercury and some plasma microRNA(miRNA) levels associated with neurological diseases in patientswith amalgam filling and dentists. Methods: This study included 30 patients with amalgam filling, 30dentists, and 30 healthy individuals as the control group. Circulatingplasma miRNAs (124-3p, 125-5p, and 127-3p) were evaluated usingreal-time quantitative polymerase chain reaction analysis. Theserum mercury levels were measured using inductively coupledplasma-mass spectrometry. ANOVA and Tukey’s multiplecomparison tests were used for statistical analyses (α =.05). Results: A significant difference in serum mercury and plasmamiRNA levels was found between the groups. Significant positivecorrelations between serum mercury and plasma miRNA 125-5pand 127-3p levels were detected in the patient group (r: 0.56 and r:0.39, respectively). Serum mercury and plasma miRNA-125-5plevels showed a positive correlation in the dentist group (r: 0.37). Conclusion: Having amalgam filling caused a significant increasein serum mercury and some plasma miRNA levels (124-3p, 125-5p,and 127-3p). The presence of a positive correlation suggests thatsensitivity to neurological diseases may increase because ofmercury exposure. Alternative restorative materials should bepreferred for amalgam filling and amalgam fillings should bereplaced with other restorative materials under necessarypreventions.

PDF

___

1. Chin G, Chong J, Kluczewska A, Lau A, Gorjy S. The environmental effects of dental amalgam. Aust Dent J 2000;45:246-9.
2. Counter SA, Buchanan LH. Mercury exposure in children: a review. Toxicol Appl Pharmacol 2004;198:209-30.
3. Berlin M, Zalups RK, Fowler BA. Mercury. In: Nordberg G, Fowler RA, Nordberg M, Friberg LT (eds). Handbook on the toxicology of metals. 3rd ed. Burlington: Academic Press, 2007.
4. Neghab M, Choobineh A, Zadeh JH, Ghaderi E. Symptoms of Intoxication in Dentists Associated with Exposure to Low Levels of Mercury. Ind Health 2011;49:249-54.
5. Rohling ML, Demakis GJ. A meta‐analysis of the neuropsychological effects of occupational exposure to mercury. Clin Neuropsychol. 2006;20:108‐132.
6. Langan DC, Fan PL, Hoos AA. The use of mercury in dentistry: a critical review of the recent literature. J Am Dent Assoc 1987;115:867- 80.
7. Yip HK, Li DK, Yau DC. Dental amalgam and human health. Int Dent J 2003;53:464-8.
8. Godfrey ME, Wojcik DP, Krone CA. Apolipoprotein E genotyping as a potential biomarker for mercury neurotoxicity. J Alzheimers Dis 2003;5:189-95.
9. Langworth S, Bjorkman L, Elinder CG, JärupL, Savlin P. Multidisciplinary examination of patients with illness attributed to dental fillings. J Oral Rehabil 2002;29:705-13.
10.Hock C, Drasch G, Golombowski S, Müller-Spahn F, Willershausen-Zönnchen B, Schwarz P, et al. Increased blood mercury levels in patients with Alzheimer's Disease. J Neural Transm 1998;105:59-68.
11.Chia S, Ong C, Lee S, Tsakok F. Blood concentrations of lead, cadmium, mercury, zinc, and copper and human semen parameters. Arch Androl. 1992;29:177-83.
12.Dursun A, Yurdakok K, Yalcin SS, Tekinalp G, Aykut O, Orhan G, et al. Maternal risk factors associated with lead, mercury and cadmium levels in umbilical cord blood, breast milk and newborn hair. The Journal of Maternal-Fetal & Neonatal Medicine. 2016;29:954-61.
13.Fok TF, Lam HS, Ng PC, Yip AS, Sin NC, Chan IH, et al. Fetal methylmercury exposure as measured by cord blood mercury concentrations in a mother–infant cohort in Hong Kong. Environ Int. 2007;33:84-92.
14.Leung TY, Choy CMY, Yim SF, Lam CWK, Haines CJ. Whole blood mercury concentrations in sub‐ fertile men in Hong Kong. Aust N Z J Obstet Gynaecol. 2001;41:75-7.
15.Bjørklund G, Hilt B, Dadar M, Lindh U, Aaseth J. Neurotoxic effects of mercury exposure in dental personnel. Basic Clin Pharmacol Toxicol 2019;124:568-74.
16.Bilen J, Liu N, Bonini NM. A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins. Cell Cycle 2006;5:2835–8.
17.Johnson R, Noble W, Tartaglia GG, Buckley NJ. Neurodegeneration as an RNA disorder. Prog Neurobiol 2012;99:293–315.
18.Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissuespecific microRNAs from mouse. Curr Biol 2002;12:735–9.
19.Krichevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS. A microRNA array reveals extensive regulation of micro-RNAs during brain development. RNA 2003;9:1274–81.
20.Miska EA, Alvarez-Saavedra E, Townsend M, Yoshii A, Sestan N, Rakic P, et al. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol 2004;5:R68.
21.Makeyev EV, Zhang J, Carrasco MA, Maniatis T. The microRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative premRNA splicing. Mol Cell 2007;27:435–48.
22.Le MT, Shyh-Chang N, Khaw SL, Chin L, Teh C, Tay J, et al. Conserved regulation of p53network dosage by microRNA-125b occurs through evolving miRNA-target genepairs. PLoS Genet 2011;7:e1002242.
23.Khudayberdiev SA, Zampa F, Rajman M, Schratt G. A comprehensive characterization of the nuclear microRNA repertoire of post-mitotic neurons. Front Mol Neurosci Epub ahead of print 17 Oct 2013. DOI: 10.3389/fnmol.2013.00043
24.Pesch A, Wilhelm M, Rostek U, Schmitz N, WeishoffHouben M, Ranft U, et al. Mercury concentrations in urine, scalp hair, and saliva in children from Germany. J Exposure Anal Environ Epidemiol 2002;12:252-8.
25.Aydin N, Karaoglanoglu S, Yigit A, Keles MS, Kirpinar I, Seven N. Neuropsychological effects of low mercury exposure in dental staff in Erzurum, Turkey. Int Dent J 2003;53:85-91.
26.Björkman L, Sjursen TT, Dalen K, Lygre GB, Berge TLL , Svahn J, et al. Long term changes in health complaints after removal of amalgam restorations. Acta Odontol Scand 2017;75:208-19.
27.Martin MD, Broughton S, Drangsholt M. Oral lichen planus and dental materials: a case-control study. Contact Dermatitis 2003;48:331-6.
28.Erkekoğlu P, Kadıoğlu E. Mercury Poisoning And Treatment. Toxicol Bull 2013;37:6-9.
29.Heyer NJ, Echeverria D, Bittner AC, Farin FM, Garabedian CC, Woods JS. Chronic low-level mercury exposure, BDNF polymorphism, and associations with self-reported symptoms and mood. Toxicol Sci 2004;81:354–63.
30.Martin MD, Naleway C, Chou HN. Factors contributing to mercury exposure in dentists. J Am Dent Assoc 1995;126:1502–11.
31.Langworth S, Sallsten G, Barregard L, Cynkier I, Lind ML, Söderman E. Exposure to mercury vapor and impact on health in the dental profession in Sweden. J Dent Res 1997;76:1397-1404.
32.Dock L, Vahter M. Metal toxicology. In: Ballantyne B, Marrs TC and Syversen T (eds) General and applied toxicology. 2nd ed. London: Macmillan Reference Books, 1999.
33.Clarkson TW, Magos L, Myers GJ. The toxicology of mercury—current exposures and clinical manifestations. N Engl J Med 2003;349:1731-7.
34.Abraham J, Svare C, Frank C. The effects of dental amalgam restorations on blood mercury levels. J Dent Res 1984;63:71-73.
35.Nilsson B, Nilsson B. Mercury in dental practice the working environment of dental personel and their exposure to mercury vapor. Swed Den J 1986;10:1-14.
36.Molin M, Bergman B, Marklund SL, Schütz A, Skerfving S. Mercury, selenium and glutathine peroxidase before and after amalgam renoval in man. Acta Odontal Scand 1990;48:189-202.
37.Lindbohm ML, Ylöstalo P, Sallmén M, HenriksEckerman MJ, Nurminen T, Forss H, Taskinen H. Occupational exposure in dentistry and miscarriage. Occup Envirom Med 2007;64:127– 33.
38. Jirau-Colón H, González-Parrilla L, MartinezJiménez J, Adam W, Jiménez-Velez B. Rethinking the Dental Amalgam Dilemma: An Integrated Toxicological Approach Int J Environ Res Public Health 2019;16:1036.
39.McGrother CW, Dugmore C, Phillips MJ, Raymond NT, Garrick P, Baird WO. Multiple sclerosis, dental caries and fillings: a case-control study. Br Dent J 1999;187:261-4.
40.Kahrizi F, Salimi A, Noorbakhsh F, Faizi M, Mehri F, Naserzadeh P, et al. Repeated administration of mercury intensifies brain damage in multiple sclerosis through mitochondrial dysfunction. Iranian journal of pharmaceutical research: IJPR. 2016;15:834.
41.DeRouen TA, Martin MD, Leroux BG, Townes BD, Woods JS, Leitão J, et al. Neurobehavioral effects of dental amalgam in children: a randomized clinical trial. JAMA 2006;295:1784-92.
42.Li N, Pan X, Zhang J, Ma A, Yang S, Ma J, et al. Plasma levels of mir-137 and mir-124 are associated with parkinson's disease but not with parkinson's disease with depression. Neurol Sci 2017;38:761-7.
43.Kapsimali M, Kloosterman WP, De Bruijn E, Rosa F, Plasterk RHA, Wilson SW. MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system. Genome Biol 2007;8:R173.
44.Diaz NF, Cruz-Resendiz MS, Flores-Herrera H, García-López G, Molina-Hernández A. MicroRNAs in central nervous system development. Rev Neurosci 2014;25:675-86.
45.Kang Q, Xiang Y, Li D, Liang J, Zhang X, Zhou F, et al. Mir-124-3p attenuates hyperphosphorylation of tau protein-induced apoptosis via caveolin-1- pi3k/akt/gsk3beta pathway in n2a/app695swe cells. Oncotarget 2017;8:24314-26.
46.Smith P, Al Hashimi A, Girard J, Delay C, Hébert SS. In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs. J Neurochem 2011;116:240-7.
47.Fang M, Wang J, Zhang X, Geng Y, Hu Z, Rudd JA, et al. The miR-124 regulates the expression of BACE1/beta-secretase correlated with cell death in Alzheimer’s disease. Toxicol Lett 2012;209:94–105.
48.Dong RF, Zhang B, Tai LW, Liu HM, Shi FK, Liu NN. The Neuroprotective Role of miR-124-3p in a 6- Hydroxydopamine-Induced Cell Model of Parkinson’s Disease via theRegulation of ANAX5. J Cell Biochem 2018;119:269-77.
49.Barca-Mayo O, Tonelli DDP. Convergent microRNA actions coordinate neocortical development. Cell Mol Life Sci 2014;71:2975–95.
50.Chinta SJ, Andersen JK. Dopaminergic neurons. The Int J Biochemistry & Cell Biology 2005;37:942-6.
51.Le MT, Xie H, Zhou B, Chia PH, Rizk P, Um M, et al. MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Mol Cell Biol 2009;29:5290–305.
52.Roese-Koerner B, Stappert L, Koch P, Borghese L. Pluripotent stem cell-derived somatic stem cells as tool to study the role of microRNAs in early human neural development. Curr Mol Med 2013;13:707–22.
53.Boissart C, Nissan X, Giraud-Triboult K, Peschanski M, Benchoua A. miR-125 potentiates early neural specification of human embryonic stem cells. Development 2012;139:1247-57.
54.Piscopoa P, Grassob M, Puopoloa M, D'Acunto E, Talarico G, Crestini A, et al. Circulating miR-127-3p as a Potential Biomarker for Differential Diagnosis in Frontotemporal Dementia. J Alzheimers Dis 2018;65:455-64.
55.Ebrahimkhani S, Vafaee F, Young PE, Hur SSJ, Hawke S, Devenney E, et al. Exosomal microRNA signatures in multiple sclerosis reflect disease status. Sci Rep 2017;7:14293.